Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia

Ma, Jun; Zhang, Lin; Huang, Zhengyuan; Wang, Gaohua

doi:10.1186/s12991-024-00532-y

Annals of General Psychiatry

Table 1 Sociodemographic and clinical parameters of included patients with and without MetS

From: Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia

Index	Total patients (n = 274)	Non-MetS (n = 176)	MetS (n = 98)	\(\:t{/\chi\:}^{2}\)	p-value
Age - years	31.99 ± 6.72	32.2 ± 6.97	31.61 ± 6.26	0.70	0.485
Disease duration - months	37.71 ± 22.19	38.3 ± 21.25	36.65 ± 23.86	0.59	0.558
Onset age - years	26.45 ± 7.78	27.09 ± 7.7	25.31 ± 7.82	1.83	0.069
Gender - (n, %)				1.37	0.242
Female	138, 50.36%	84, 47.73%	54, 55.10%
Male	136, 49.64%	92, 52.27%	44, 44.90%
Olanzapine Dosage	15.15 ± 4.79	14.77 ± 5.01	15.82 ± 4.32	-1.81	0.072
Olanzapine concentration	47.62 ± 17.8	49.43 ± 20.58	44.37 ± 10.54	2.69	0.008*
MetS scores	0.40 ± 0.80	0.07 ± 0.76	0.99 ± 0.44	-12.66	<0.001*
MetS dimensions
WC - cm	86.52 ± 11.13	82.3 ± 10.68	94.1 ± 7.23	-10.87	<0.001*
FBG - mmol/L	4.9 ± 0.58	4.72 ± 0.46	5.26 ± 0.61	-7.43	<0.001*
SBP - mmHg	114.41 ± 8.94	113.27 ± 9.14	116.45 ± 8.24	-2.86	0.005*
DBP - mmHg	75.8 ± 8.56	74.3 ± 8.47	78.51 ± 8.08	-4.01	<0.001*
TG - mmol/L	2.83 ± 1.53	2.49 ± 1.66	3.43 ± 1.04	-5.75	<0.001*
HDL-C - mmol/L	1.11 ± 0.29	1.22 ± 0.29	0.93 ± 0.2	9.87	<0.001*
TC - mmol/L	4.25 ± 1.54	4.26 ± 1.49	4.24 ± 1.64	0.11	0.916
LDL-C - mmol/L	2.93 ± 0.81	2.83 ± 0.8	3.11 ± 0.81	-2.80	0.006*
BMI – kg/m²	25.08 ± 4.5	23.61 ± 4.3	27.73 ± 3.53	-8.08	<0.001*
BUN - mmol/L	3.94 ± 0.96	4.18 ± 1	3.53 ± 0.73	6.16	<0.001*
CRE - mmol/L	67.77 ± 11.66	68.88 ± 12.97	65.78 ± 8.55	2.37	0.019*
UA - mmol/L	443.32 ± 104.49	427.86 ± 109.82	471.08 ± 88.08	-3.34	0.001*
TSH - uIU/mL	2.73 ± 1.96	2.28 ± 1.59	3.52 ± 2.3	-5.27	<0.001*
FT₃ - pmol/L	2.97 ± 0.49	3.03 ± 0.46	2.86 ± 0.51	2.85	0.005*
FT₄ - pmol/L	10.51 ± 4.39	10.81 ± 4.14	9.97 ± 4.78	1.46	0.145
ALT	32.44 ± 29.37	33.09 ± 35.06	31.27 ± 14.39	0.61	0.546
AST	26.16 ± 16.5	27.36 ± 18.37	24 ± 12.24	1.81	0.071
QT-c - ms	420.41 ± 28.18	413.2 ± 26.16	433.35 ± 27.14	-5.96	<0.001*
PANSS	54.89 ± 6.02	54.61 ± 6.13	55.38 ± 5.83	-1.01	0.315
CGI-SI	2.28 ± 0.62	2.29 ± 0.61	2.27 ± 0.65	0.31	0.755
TESS	4.69 ± 3.62	4.52 ± 3.4	5.01 ± 3.98	-1.04	0.302
GAF	77.93 ± 8.91	77.89 ± 9.13	78 ± 8.53	-0.10	0.920
BARS	0.5 ± 1.21	0.4 ± 0.96	0.68 ± 1.54	-1.63	0.105
RESES	1.61 ± 2.12	1.55 ± 2.03	1.71 ± 2.27	-0.63	0.528

MetS: Metabolic syndrome; WC: waist circumference; FBG: fasting blood glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglycerides; HDL-C: high density lipoprotein cholesterol; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; BMI: body mass index; BUN: blood urea nitrogen; CRE: blood creatinine; UA: blood uric acid; TSH: thyroid stimulating hormone; FT₃: free triiodothyronine; FT₄: free tetraiodothyronine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; QT-c: QT-c interval; PANSS: Positive and Negative Syndrome Scale; CGI-SI: Clinical Global Impression Scale - Severity of Illness; TESS: Treatment Emergent Symptom Scale; GAF: Global Assessment of Functioning scale; BARS: Barnes Akathisia Rating Scale; RESES: Rating Scale for Extrapyramidal Side Effects. *P<0.05

Back to article page

ISSN: 1744-859X

Contact us

Submission enquiries: journalsubmissions@springernature.com